Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 65

1.

Naturally occurring tumor-specific CD8+ T-cell precursors in individuals with and without cancer.

Karanikas V, Zamanakou M, Soukou F, Kerenidi T, Gourgoulianis KI, Germenis AE.

Immunol Cell Biol. 2010 Jul;88(5):575-85. doi: 10.1038/icb.2010.8. Epub 2010 Feb 9.

PMID:
20142837
2.

Baseline levels of CD8+ T cells against survivin and survivin-2B in the blood of lung cancer patients and cancer-free individuals.

Karanikas V, Soukou F, Kalala F, Kerenidi T, Grammoustianou ES, Gourgoulianis KI, Germenis AE.

Clin Immunol. 2008 Nov;129(2):230-40. doi: 10.1016/j.clim.2008.07.024. Epub 2008 Sep 13.

PMID:
18789878
3.

Induction of human tumor-associated differentially expressed gene-12 (TADG-12/TMPRSS3)-specific cytotoxic T lymphocytes in human lymphocyte antigen-A2.1-positive healthy donors and patients with advanced ovarian cancer.

Bellone S, Anfossi S, O'Brien TJ, Cannon MJ, Silasi DA, Azodi M, Schwartz PE, Rutherford TJ, Pecorelli S, Santin AD.

Cancer. 2009 Feb 15;115(4):800-11. doi: 10.1002/cncr.24048.

5.

Naturally acquired MAGE-A10- and SSX-2-specific CD8+ T cell responses in patients with hepatocellular carcinoma.

Bricard G, Bouzourene H, Martinet O, Rimoldi D, Halkic N, Gillet M, Chaubert P, Macdonald HR, Romero P, Cerottini JC, Speiser DE.

J Immunol. 2005 Feb 1;174(3):1709-16.

6.

Small cell lung carcinomas express shared and private tumor antigens presented by HLA-A1 or HLA-A2.

Yamazaki K, Spruill G, Rhoderick J, Spielman J, Savaraj N, Podack ER.

Cancer Res. 1999 Sep 15;59(18):4642-50.

7.

The spontaneous CD8+ T-cell response to HLA-A2-restricted NY-ESO-1b peptide in hepatocellular carcinoma patients.

Shang XY, Chen HS, Zhang HG, Pang XW, Qiao H, Peng JR, Qin LL, Fei R, Mei MH, Leng XS, Gnjatic S, Ritter G, Simpson AJ, Old LJ, Chen WF.

Clin Cancer Res. 2004 Oct 15;10(20):6946-55.

8.

Natural CD8+ T-cell responses against MHC class I epitopes of the HER-2/ neu oncoprotein in patients with epithelial tumors.

Sotiropoulou PA, Perez SA, Voelter V, Echner H, Missitzis I, Tsavaris NB, Papamichail M, Baxevanis CN.

Cancer Immunol Immunother. 2003 Dec;52(12):771-9. Epub 2003 Sep 10.

PMID:
13680193
9.

Analysis of cytotoxic T lymphocytes and Fas/FasL in Japanese patients with non-small cell lung cancer associated with HLA-A2.

Yoshimura C, Nomura S, Kanazawa S, Kuwana M, Muramatsu M, Yamaguchi K, Fukuhara S.

J Cancer Res Clin Oncol. 2002 Nov;128(11):581-8. Epub 2002 Oct 25.

PMID:
12458337
10.

Analysis of MAGE-3-specific cytolytic T lymphocytes in human leukocyte antigen-A2 melanoma patients.

Valmori D, Liénard D, Waanders G, Rimoldi D, Cerottini JC, Romero P.

Cancer Res. 1997 Feb 15;57(4):735-41.

11.

Vaccination with mage-3A1 peptide-pulsed mature, monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma.

Thurner B, Haendle I, Röder C, Dieckmann D, Keikavoussi P, Jonuleit H, Bender A, Maczek C, Schreiner D, von den Driesch P, Bröcker EB, Steinman RM, Enk A, Kämpgen E, Schuler G.

J Exp Med. 1999 Dec 6;190(11):1669-78.

12.

Tumor specific CD8+ T cells in patients with lung cancer and healthy individuals.

Karanikas V, Germenis A.

J BUON. 2009 Sep;14 Suppl 1:S153-7. Review.

PMID:
19785058
13.

Lack of tumor recognition by cytolytic T lymphocyte clones recognizing peptide 195-203 encoded by gene MAGE-A3 and presented by HLA-A24 molecules.

So T, Hanagiri T, Chapiro J, Colau D, Brasseur F, Yasumoto K, Boon T, Coulie PG.

Cancer Immunol Immunother. 2007 Feb;56(2):259-69. Epub 2006 Jun 7.

PMID:
16758204
14.

Induction of cytotoxic T lymphocytes against human cancer cell lines using dendritic cell-tumor cell hybrids generated by a newly developed electrofusion technique.

Imura K, Ueda Y, Hayashi T, Itoh T, Shimizu K, Tamai H, Yano Y, Naito K, Kohara J, Nakane K, Matsuura Y, Takeda A, Takeda T, Kawai K, Yamagishi H.

Int J Oncol. 2006 Sep;29(3):531-9.

PMID:
16865268
15.

Screening of HLA-A24-restricted epitope peptides from prostate-specific membrane antigen that induce specific antitumor cytotoxic T lymphocytes.

Horiguchi Y, Nukaya I, Okazawa K, Kawashima I, Fikes J, Sette A, Tachibana M, Takesako K, Murai M.

Clin Cancer Res. 2002 Dec;8(12):3885-92.

16.

High frequency of prostate antigen-directed T cells in cancer patients compared to healthy age-matched individuals.

Forsberg O, Carlsson B, Malmström PU, Ullenhag G, Tötterman TH, Essand M.

Prostate. 2009 Jan 1;69(1):70-81. doi: 10.1002/pros.20858.

PMID:
18814178
17.

CD8+CD28- cells and CD4+CD25+ regulatory T cells in the peripheral blood of advanced stage lung cancer patients.

Karagöz B, Bilgi O, Gümüs M, Erikçi AA, Sayan O, Türken O, Kandemir EG, Oztürk A, Yaylaci M.

Med Oncol. 2010 Mar;27(1):29-33. doi: 10.1007/s12032-008-9165-9. Epub 2009 Jan 16.

PMID:
19148592
18.

Identification of MHC class II-restricted T-cell epitopes in prostate-specific membrane antigen.

Schroers R, Shen L, Rollins L, Xiao Z, Sonderstrup G, Slawin K, Huang XF, Chen SY.

Clin Cancer Res. 2003 Aug 15;9(9):3260-71.

19.

Characterization of preexisting MAGE-A3-specific CD4+ T cells in cancer patients and healthy individuals and their activation by protein vaccination.

Tsuji T, Altorki NK, Ritter G, Old LJ, Gnjatic S.

J Immunol. 2009 Oct 1;183(7):4800-8. doi: 10.4049/jimmunol.0900903. Epub 2009 Sep 4.

20.

Supplemental Content

Support Center